Mirum Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mirum Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 73.5% per year.
Key information
-12.9%
Earnings growth rate
13.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 73.5% |
| Return on equity | -43.0% |
| Net Margin | -32.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Jan 08Mirum Pharma: Buy At Dips For Volixibat Potential
Dec 25Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues
Dec 09
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
Nov 15Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Revenue & Expenses Breakdown
How Mirum Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 307 | -100 | 192 | 128 |
| 30 Jun 24 | 264 | -109 | 178 | 122 |
| 31 Mar 24 | 224 | -159 | 161 | 111 |
| 31 Dec 23 | 186 | -163 | 146 | 103 |
| 30 Sep 23 | 145 | -164 | 126 | 103 |
| 30 Jun 23 | 116 | -176 | 112 | 103 |
| 31 Mar 23 | 96 | -129 | 100 | 106 |
| 31 Dec 22 | 77 | -136 | 89 | 107 |
| 30 Sep 22 | 52 | -42 | 82 | 104 |
| 30 Jun 22 | 39 | -53 | 76 | 108 |
| 31 Mar 22 | 32 | -70 | 69 | 117 |
| 31 Dec 21 | 19 | -84 | 59 | 131 |
| 30 Sep 21 | 16 | -179 | 47 | 133 |
| 30 Jun 21 | 11 | -153 | 36 | 119 |
| 31 Mar 21 | 0 | -132 | 27 | 102 |
| 31 Dec 20 | 0 | -103 | 23 | 82 |
| 30 Sep 20 | 0 | -84 | 20 | 66 |
| 30 Jun 20 | 0 | -78 | 18 | 62 |
| 31 Mar 20 | 0 | -68 | 15 | 55 |
| 31 Dec 19 | 0 | -53 | 12 | 43 |
| 30 Sep 19 | 0 | -61 | 8 | 32 |
Quality Earnings: MIRM is currently unprofitable.
Growing Profit Margin: MIRM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIRM is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare MIRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: MIRM has a negative Return on Equity (-43.02%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 16:33 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |